ESMO: Merck Sees Keytruda-Lenvima Potential In Melanoma, Hard-To-Treat Cancers
Also Promising In Ovarian And Colorectal
Keytruda-Lenvima picked out as pick of combination therapies from the European cancer congress.
You may also be interested in...
Oncology is an area where the Swiss major has long been a dominant player, and Bill Anderson highlighted programs to Scrip which Roche hopes will help extend that dominance.
Merck/Eisai face US speed bump for combo in first-line liver cancer after FDA decision and although their Phase III trial is already enrolled, completion is not due until 2022, giving time for new competitor to make its mark.
The Paris-headquartered company has thrown in the towel on its oral SERD, leaving Roche, Eli Lilly and AstraZeneca to pursue Menarini in the field.